Thera-SAbDab

COLTUXIMAB

> Structural Summary

Therapeutic	Coltuximab
Target	CD19
Heavy Chain	QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS
Light Chain	EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK
100% seqID Fv Structure	6ani [Fvs: HL, IM]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	6ani [Fvs: HL, IM]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb ADC
Isotype	G1
Highest Clinical Trial (June '19)	Phase-II
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2013
INN Year Recommended	2014
Companies Involved	ImmunoGen
Conditions Approved	na
Conditions Active	Diffuse large B cell lymphoma
Conditions Discontinued	Precursor cell lymphoblastic leukaemia-lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]